Open Access<p>Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study</p>
Author(s) -
Guosheng Yuan,
Xiangdong Cheng,
Qi Rong Li,
Meirong Zang,
Wei Huang,
Wenzhe Fan,
Tao Wu,
Jian Ruan,
Weiyu Dai,
Wenxuan Yu,
Mian Chen,
Yabing Guo,
Xiaoyun Hu,
Jinzhang Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s286169
Subject(s) - medicine , hepatocellular carcinoma , apatinib , retrospective cohort study , tolerability , progression free survival , portal vein , response evaluation criteria in solid tumors , oncology , surgery , cohort , gastroenterology , progressive disease , chemotherapy , adverse effect
Previous trials demonstrated that anti-angiogenesis or anti-programmed death protein 1 (PD-1) monotherapy showed unsatisfied effect in advanced hepatocellular carcinoma (HCC). No study existed that focus on the effects of camrelizumab and apatinib ("C+A") combination therapy for HCC patients with the location and extent of portal vein tumor thrombus (PVTT) as the main variable being assessed. This study was to compare the efficacy and tolerability of "C+A" for HCC patients with PVTT.